Target intelligence / Profile preview

Alpha-tectorin (TECTA)

Target
TECTA
Molecular classification
Other (extracellular matrix protein, GPI-anchored protein)
01

Overview

Alpha-tectorin is a large extracellular matrix glycoprotein encoded by the TECTA gene, predominantly found in the tectorial membrane of the cochlea in the inner ear[3][5]. It is critical for normal hearing by contributing to the mechanical properties of the tectorial membrane, enabling the proper transmission of sound-induced vibrations to sensory hair cells, which is essential for auditory signal transduction[1][3][4][5]. Alpha-tectorin is a GPI-anchored protein with multiple protein–protein interaction domains that organize the structure and assembly of the tectorial membrane[1]. Mutations in the TECTA gene cause both autosomal dominant (DFNA8/12) and autosomal recessive (DFNB21) forms of nonsyndromic sensorineural hearing loss, due to defective structure or loss of function of the tectorial membrane[2][3][4]. It is not currently considered a conventional therapeutic target (e.g. receptor or enzyme), and there are no known drugs that directly interact with alpha-tectorin[2][3][5]. However, TECTA gene testing can serve as a biomarker to diagnose genetic forms of hearing loss and guide family counseling for hereditary deafness[2][3].

Other names
DFNA12DFNA8DFNB21TECTA_HUMANtectorin alpha
02

Biological functions

Structural component of the tectorial membraneExtracellular matrix organizationAuditory transduction
03

Disease associations

Neurodegenerative disease (sensorineural hearing loss: nonsyndromic - dominant [DFNA8/12], recessive [DFNB21])
04

Biomarkers

Mutations in TECTA used as genetic biomarkers for specific forms of hereditary hearing loss

Beyond the preview

Go deeper on Alpha-tectorin (TECTA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-tectorin (TECTA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call